| Name | Title | Contact Details |
|---|---|---|
Brigid Hayes |
Associate Director - IT Systems Program Manager | Profile |
Scott Hines |
Associate Director - Global Information Systems Quality | Profile |
Mike Boland |
Sr. Director - Counsel - eDiscovery and Information Management | Profile |
Francisco Toste |
VP Supply Chain Design and Transformation | Profile |
Charlie Haddad |
VP - Chief Enterprise Business Architect | Profile |
Find a rehab center to treat your drug or alcohol addiction, eating disorder, or mental illness. Connect with us and get help for your addiction.
At KBP we are consistently reminded that patient care is the end goal of what we do daily.
Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.
Azurity Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the needs of patients, especially children and the elderly, that require customized user-friendly drug formations. Our products have benefited millions of patients whose needs are not served by other commercially available therapies. AZURITY VALUES: COMPASSION - We put the needs of our patients and caregivers at the center of everything we do, including the decisions we make. QUALITY - We aim to provide our patients with the highest-quality, safe, and effective therapies for their needs. INNOVATION - We use the best science and manufacturing techniques to deliver cost-effective, high-value medications to our patients. A COMPANY OF DIFFERENCE MAKERS As Azurity grows to meet new challenges, and serve new patient groups, one thing never changes: our dedication to the lives of others. Whether through our innovative medications, our focus on creating a positive company environment, or our community and volunteer work, we are committed to having a positive impact on the lives of those we touch.
ExonHit Therapeutics is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.